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Synopsis 
 
Gene therapy is an experimental technique in which a disease causing mutated gene ia 
a replaced with a healthy functioning copy of the gene. Gene therapy is represents one of the 
most important developments in the field of medicine, but before it can be realized in 
practice, certain technical problems common to all methods of gene delivery must be 
overcome. Since the biological surfaces are negatively charged, entry of negatively charged 
plasmid DNA spontaneously into the body cells is an inefficient process. Because of this the 
clinical success of gene therapy is so critically dependent on the use of efficient gene delivery 
agents (commonly referred to as “transfection vectors”).  An ideal vector should allow 
efficient and selective transduction of the target cell of interest should be able to provide 
sustained gene expression at levels necessary for achieving therapeutic effects and should be 
safe. The transfecting vectors are of two categories; viral & non-viral vectors. Although viral 
vectors are the most efficient gene transfer vehicles, there are a multitude of potentially 
adverse effects associated with their use in gene therapy. These complications are 
increasingly making non viral transfection vectors as the vectors of choice in gene therapy. 
Non viral vectors offer many advantages over viral vectors including lower toxicity, 
immnogenicity, capability for delivery large DNA to be delivered, ease of large scale 
production and low frequency of integration etc. The non viral methods are mainly classified 
into physical and chemical methods. Physical methods involve direct introduction of genes 
into the cells e.g. microinjection, electroporation, gene gun and the chemical methods involve 
use of chemicals including DEAE-Dextran, calcium phosphate precipitation, cationic 
amphihphiles, cationic polymers, dendrimers, cationic amphiphiles etc. for delivering the 
DNA to target cells. DNA vaccines are originally developed from gene therapy experiments. 
DNA vaccines: DNA vaccination or immunization is a novel technique used to efficiently 
stimulate humoral and cellular immune responses to protein antigens. Direct injection of 
genetic material (plasmid DNA containing encoded antigen) into a living host causes 
expression of the introduced gene in a small population of its cells. This inappropriate gene 
expression within the host has important immunological consequences resulting in the 
specific immune activation by the host against the administered antigen in the form of DNA 
vaccine. The basis for DNA vaccines rests on the observation that direct in vitro and in vivo 
gene transfer of recombinant DNA by different types of techniques resulted in expression of 
antigenic protein. DNA vaccines have many advantages over traditional vaccines. They are 
able to induce the expression of antigens that resemble native viral epitopes more closely than 
standard vaccines do since live attenuated and killed vaccines are often altered in their protein 
structure and antigenicity. Rapid and large-scale production are feasible at cost considerably 
lower than that for traditional vaccines and they are also very temperature stable making their 
transportation/storage least problematic. DNA vaccines encoding several antigens or proteins 
can be delivered to the host in a single dose only requiring a microgram of plasmids to induce 
immune responses. In contrast to conventional vaccines, DNA vaccines elicit cell-mediated 
(cellular immunity) as well as antibody-mediated (humoral immunity) immune responses. 
Theses nucleic acid based vaccines are still in experimental stage and are being applied to a 
number of viral, bacterial and parasitic models of disease as well as to mouse tumor models.  
Mechanism of DNA vaccine: After intramuscular administration of plasmid DNA, the DNA 
is mostly taken up by the muscle cells (in case of naked DNA) or by antigen presenting cells 
(APCs) like DC or macrophages infiltrating the sight of injection especially when liposomes 
or cationic microparticles are used as DNA vaccine delivery vehicles. The protein expressed 
by direct transfection of APCs is fragmented to smaller peptides by the proteosome complex 
in the cytosol.  These fragmented peptides are complexed with MHC-I peptides of APCs and 
the antigen fragment MHC I complexes are presented to the cell surface of APCs. The CD8+ 
cells then recognize the antigenic peptides in association with MHC-I complex on the surface 
of APCs (Figure 1). These cytotoxic T-lymphocytes (CTLs) specialize in killing of infected 
cells upon activated by co-stimulatory molecules present on the surface of APCs (Figure 2). 
This pathway is called direct priming.   
 
 
 
 
 
 
  
                                       
 
 
 
 
 
 
 
                                Figure 1: Major Histocompatability Complex pathway  
 
                      Alternatively, if the myocytes are transfected, the antigenic protein has to be 
transferred to the APCs for induction of CTL response due to the lack of co-stimulatory 
molecules in myocytes. The protein taken up by APCs is degraded in the endosome 
compartments and the peptide fragments are complexed with MHC-II complexes and 
presented to CD4+ T-cells (Figure 2). The CD4+ cells develop into T lymphocytes with a T 
helper (Th) response leading to either inflammation (Th-1 response) or antibody formation 
(Th-2 response). The Th1 is associated with production of Interleukin-2 (IL-2) and 
Interferon-Gamma (IFN-γ) and may have a greater role in T cell proliferation and 
inflammation while the Th2 is associated with the production of IL-4, 5, 6 & 10 and may be 
more involved in B cell development and proliferation (Figure 1). On the other hand, if the 
exogenous protein uptaken by the APC escapes endosomal degradation, and presented to the 
CD8+ T-cells via MHC-I, it results in the generation of CTL response. This is called cross 
presentation. In addition, the antigenic protein released by the myocytes into the surroundings 
may directly stimulate B-cells by binding to their immunoglobulin-like receptors thereby 
inducing an antibody mediated immune response.  
 
 
 
 
Figure 2: Role of Dendritic cells (DCs) in specific immunity 
 
Dendritic cells:  Dendritic cells were first described by Paul Langerhans (and hence are also 
known as Langerhans cells) in the late nineteenth century. The term "dendritic cells" was 
coined by Ralph M. Steinman. DCs are rare and heterogeneous population of antigen 
presenting cells which can be encountered in the body at different sites according to their 
development and function. Dendritic cells are distinguished from the macrophages and 
granulocytes by different features including dendritic or veiled morphology (Figure 3), weak 
adherence to plastic, and distinct antigenic markers including high levels of MHC class II 
products and new intracellular antigens and strong mixed lymphocyte reaction (MLR) 
responses. For mouse, proliferating precursors of DCs that can be expanded into DC lines in 
vitro with GM-CSF(Granulocyte macrophage colony stimulating factor) and IL-4 
(Interleukin) are present both in bone marrow and peripheral blood. These sources are widely 
used because of its greater DC yield. For human DCs, mostly they have been isolated from 
peripheral blood monocytes (PBMC) by using density based purification approaches. Since 
circulating DC precursors only represent less than 1% of the PBMC, it is difficult to obtain a 
sufficient number of DC for in vitro and in vivo studies even after leukapheresis (separation 
of WBC from blood). More recent approaches for generating human DC are from CD14+ 
monocytes or CD34+ precursor cells. CD 14+ monocytes can be differentiated into immature 
DC by culturing with GM-CSF and IL-4, whereas most protocols to produce DC from CD34+ 
cells include additional cytokines such as stem cell factor (SCF), Flt3 ligand and TNF-alpha.  
          Dendritic cells are the most professional APCs and have the unique ability to generate 
primary immune responses to antigens such as tumor associated antigen (TAA) and have a 
key function in maintaining the immunological memory. Immature DCs can take up antigens 
very efficiently by a variety of mechanisms. Soluble antigens are taken up by 
macropinocytosis and adsorptive or receptor mediated endocytosis through the mannose 
receptor, an 180kDa transmembrane protein present on cell surface of macrophages and 
immature dendritic cells. Mannose receptor mediates phagocytosis and endosytosis of 
antigens containing mannose, fucose and N-acetyl glucosamine etc. These mechanisms make 
antigen presentation much more efficient and require a lower antigen concentration compared 
to other APC like macrophages.  
 
 
 
 
 
 
 
 
 
Figure 3: Picture of dendritic cells 
 
 
 Use of Non viral Transfection vectors in Dendritic cell based genetic immunization:  
Lack of efficient tumor antigen presentation in DCs in cancer patients has led to the use of 
DC-based vaccines. The tumor antigens are taken up by dendritic cells, processed and 
presented to the T cells along with the appropriate costimulatory signals. DCs are 
professional cells and strictly control the trafficking of molecules across their cell 
membranes. It is difficult to transfer genes into the nucleus of DCs. Once activated by the 
DCs, the cytotoxic T cells recognize and destroy the tumor cells expressing the tumor 
antigen. DCs are collected from the blood of the patient (a process called leukapheresis) and 
"loaded" with tumor antigens from the patient's own tumor cells. These DCs are then 
reintroduced into the patient and stimulate the immune system. Many studies have been 
performed on loading DCs with different antigens for in vitro assays or cancer 
immunotherapy and efficient transfection has been achieved with viral vectors. Although viral 
transduction is efficient, there is a need for DC-based immunotherapy which would be 
without risk of exposing individuals to other viral genes or integration of the viral genome. 
Thus, development of  effective and safe nonviral method for DC transfection would greatly 
advance the field of DC based genetic immunization. 
Non viral methods achieve lower gene transduction efficiency of DCs than adenoviral 
vectors. However, despite the low trasfection efficiency, transfected DCs are potent immune 
stimulators.  Such inefficient gene transfer to DCs, low levels of gene expression, or low cell 
viability by nonviral transfection methods have limited the progress of DC based nonviral 
immunotherapy. The highest nonviral transfection efficiency of plasmid DNA in DCs has 
been achieved by nucleofection. This method resulted up to 56% efficiency but only 37% 
viability of the transfected DCs after 24 h. It has been demonstrated that single injection of 
500–1,000 transfected DCs can generate the immune response comparable to that of 
conventional genetic immunization. Low levels of tyrosine has been observed when in vitro 
generated DCs were transfected with the tyrosinase gene with lipofection, but tyrosine 
expressed DCs were able to activate tyrosine specific T cells. Monocyte derived DCs 
transiently transfected with MART-1, have been shown to be capable of stimulating naïve 
CD8+ T cells with cytolytic activity against himan HLA matched tumor cells expressing 
MART-1. DCs transfected with plasmid encoding the human papilloma virus E7 antigen or 
P53 have been shown to be capable of inducing protective responses against tumors bearing 
these antigens. Transfected murine DCs with plasmid DNA contain the gp 100 gene protected 
mice from subsequent challenge with tumors expressing gp 100. Immunization with  
transfected DC (where transfection efficiency is only 1%) with a complex of cationic peptide 
CL22 and TRP2 antigen was shown to be capable of protecting mice from lethal challenge 
with tumor cells.  
Mannose receptor mediated gene delivery is an emerging non-viral method for 
targeting APCs in DC based genetic immunization. Previous reports demonstrated use of 
mannan coated liposomes for intranasal delivery of HIV-1 DNA vaccine, mannan-coated 
cationic nanoparticles for topical immunization, mannosylated cationic liposomes, and  
mannosylated chitosan/DNA nanoparticles and oxidized and reduced mannan poly-l-lysine 
have been reported for delivering DNA vaccine to APCs through mannose receptor of APCs.  
There remains a clear need for designing systemically more efficacious cationic liposomal 
reagents to transfect DCs efficiently with plasmid encoded TAAs for targeting DNA vaccines 
to the mannose receptors expressed on cell surface of DCs. 
 
Present thesis: 
Clinical success of the emerging field of dendritic cell (DC) based DNA vaccination 
remains crucially dependent on targeting of antigen encoded genes to antigen presenting cells 
(APCs) mainly dendritic cells. Thus, targeting vaccines to APCs is essential for the induction 
and modulation of immune responses. Mannosylated vectors have been widely used to target 
DNA vaccines to APCs via mannose receptors over expressed on the cell surface of APCs. 
The non-carbohydrate carbocyclic Shikimic acid and Quinic acid are potential mannose 
receptor ligands since they possess the vicinal diol functionalities at the C-4 & C-5 positions. 
More importantly, the presence of a carboxylic acid groups in Shikimic & Quinic acids 
renders functionalization more facile than in mannose. Chapter 1 of the present thesis 
delineates for the first time the systemic potential of cationic amphiphiles with mannose 
mimicking quinic acid (lipid 1, Figure 4) and shikimic acid (lipid 2, Figure 4) head groups in 
delivering therapeutic DNA vaccine for use in DC based genetic immunization.  
 
  
 
 
 
 
 
 
The glycomimicking amphiphiles containing quinic acid (lipid 1) and shikimic acids 
(lipid 2) head groups and also control mannosyl analog (lipid 3) were designed and 
synthesized (Figure 4). The glycomimicking cationic amphiphiles 1 & 2 as well as the control 
mannosylated cationic amphiphile 3 were targeted DNA to APCs via mannose receptor.  All 
the three amphiphiles in combination with equimolar cholesterol as co-lipid were found to be 
transfection efficient across the entire lipid: DNA charge ratios 1:1 to 8:1.  Importantly, the 
findings described in Chapter 1 demonstrate that subcutaneous administration of DCs pre-
transfected with electrostatic complex of pCMV-MART1 plasmid DNA (encoding MART1 
antigen of human melanoma tumor) and cationic liposomes of glycomimicking amphiphile 
with shikimic acid head-group (2) provided more tumor protective effect in C57BL/6 mice 
challenged with aggressive B16F1 melanoma tumor than subcutaneous administration of the 
corresponding lipoplex of mannosylated cationic glycolipid (3). 
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Figure 4: Chemical Structures of lipid 1-3
  
 
 
 
 
 
 
 
 
 
The findings described in Chapter 1 demonstrated the systemic potential of cationic 
glycomimicking amphiphiles for use in genetic immunization. However the poor DC 
transfection efficacies (3%) of these first generation cationic glycomimicking amphiphiles 
clearly justify needs for pursuing further in depth structure activity investigation aimed at 
finding more efficient cationic glycomimicking amphiphiles as DNA vaccine carriers in DC 
based genetic immunization. To this end in Chapter 2 describes syntheses of novel cationic 
amphiphiles containing mono and di glycomimicking amphiphiles and their control mannosyl 
analoges in the head group region (Figure 5A &B, Lipids 1-14).  
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Figure 5A: Chemical structures of lipids 1-7
  
 
 
 
 
 
 
 
 
 
The structure activity investigation described in Chapter 2 revealed that lysinylated 
cationic amphiphiles containing di-quinic acid, di-shikimic acid and di-mannose head groups 
(Figure 5A, lipids 1-7) are significantly less transfection efficient compared to their mono 
shikimic and mono quinic analogs (Figure 5B, lipids 8-14) across the entire lipid:DNA 
charge ratios 1:1 to 8:1 in murine macrophage cell (RAW 264.7) with DOPE as a co-lipid. 
Importantly the transfection efficiency of mono shikimic and mono quinic acid analogs 
(Figure 5B, lipids 8-14) were reduced up to 50-60% in RAW 264.7 cells pretreated with 
mannan. These observations confirmed that these cationic lipids deliver the genes via 
mannose receptor. Enhanced transfection efficiencies of the lysinylated cationic amphiphiles 
with mono shikimic and mono quinic acid and their mannosyl analogs (Figure 5B, lipids 9, 
12 &14) were observed in mbm DCs.  Most importantly immunization of mice with DCs pre 
transfected with the complexes of MART 1 DNA and lipid 9, 12 & 14 provided significant 
tumor inhibition in C57Bl6 mice challenged with B16 melanoma cells. 
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Finally, toward probing the efficacies of glycomimicking cationic amphiphiles 
containing cholesterol unit as the hydrophobic tails in DNA vaccination, lipids 1 & 2 (Figure 
6) with quinic acid and shikimic acid head groups, respectively and the control mannosyl 
analog lipid 3 (Figure 6) were designed and synthesized. The findings delineated in the 
concluding Chapter 3 demonstrate that cationic mannose mimicking cholesterol based 
amphiphiles containing quinic acid and shikimic acid  (Figure 6, lipid 1&2 respectively) 
head-groups are more transfection efficient compared to their control mannosyl analogue 
(Figure 6, lipid 3) in RAW cell. Lipids 1 & 2 with equimolar DOPE as a co-lipid were most 
efficient at 2:1 and 1:1 lipid: DNA charge ratios.  
Thus the structure activity findings summarized in Chapters 1-3, taken together, are 
consistent with the supposition that mannose mimicking cationic amphiphiles with aliphatic 
hydrocarbon tails hold more therapeutic promise than their cholesterol analogs for use in DC 
based genetic immunization. 
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